NuVasive (NUVA) jumps 11.7% after disclosing that preliminary 2012 revenues climbed 15% to...

|By:, SA News Editor

NuVasive (NUVA) jumps 11.7% after disclosing that preliminary 2012 revenues climbed 15% to $619M, above previous guidance of $601-606M and analyst consensus of $604.4M. NuVasive expects 2013 sales of $655M vs Street forecasts of $638.16M. "We anticipate that our market share taking strategy and momentum can be sustained in 2013," says CEO Alex Lukianov, who's due to present at the JPM Healthcare conference today. (PR)